On 19 December, Bambino Gesù Pediatric Hospital and INFN signed a five-year collaboration agreement to enhance the study and development of radiopharmaceuticals, to improve oncological radiotherapy techniques and to contribute to the optimization of increasingly precise and personalized treatments. In particular, the goal is to develop new-generation PET radiopharmaceuticals, capable of offering superior diagnostic precision, perfecting radiometabolic therapies and personalizing radiotherapy. Biokinetic and biodistribution analyses will also be conducted to monitor how radiopharmaceuticals are distributed and act in the body over time. One of the techniques involves the use of wearable devices, such as T-shirts or pajamas, equipped with dosimeters for continuous and less invasive monitoring, to contribute to improving the quality of life of patients.
